Critics Rip Big Pharma Alternative To FDA Warning Label Plan

Law360, New York (April 29, 2015, 3:45 PM EDT) -- An industry-backed alternative to the U.S. Food and Drug Administration’s plan to let generic-drug makers unilaterally update their warning labels is a ruse to expand immunity from product liability suits, consumer advocates and plaintiffs' lawyers charged in letters released Tuesday.

The letters were posted online after a deadline passed to comment on the FDA’s plan, which would effectively undo the 2011 U.S. Supreme Court decision in Pliva v. Mensing that shielded generic-drug firms from failure-to-warn liability. A number of prominent groups and law firms took issue with an alternative to that plan being pushed by Pharmaceutical Research and Manufacturers of America...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS